Literature DB >> 28059647

Simulating vasogenic brain edema using chronic VEGF infusion.

Martin Piazza1, Jeeva Munasinghe2, Roger Murayi1, Nancy Edwards1, Blake Montgomery1, Stuart Walbridge1, Marsha Merrill1, Prashant Chittiboina1.   

Abstract

OBJECTIVE To study peritumoral brain edema (PTBE), it is necessary to create a model that accurately simulates vasogenic brain edema (VBE) without introducing a complicated tumor environment. PTBE associated with brain tumors is predominantly a result of vascular endothelial growth factor (VEGF) secreted by brain tumors, and VEGF infusion alone can lead to histological blood-brain barrier (BBB) breakdown in the absence of tumor. VBE is intimately linked to BBB breakdown. The authors sought to establish a model for VBE with chronic infusion of VEGF that can be validated by serial in-vivo MRI and histological findings. METHODS Male Fischer rats (n = 182) underwent stereotactic striatal implantation of MRI-safe brain cannulas for chronic infusion of VEGF (2-20 µg/ml). Following a preinfusion phase (4-6 days), the rats were exposed to VEGF or control rat serum albumin (1.5 µl/hr) for as long as 144 hours. Serial MRI was performed during infusion on a high-field (9.4-T) machine at 12-24, 24-36, 48-72, and 120-144 hours. Rat brains were then collected and histological analysis was performed. RESULTS Control animals and animals infused with 2 µg/ml of VEGF experienced no neurological deficits, seizure activity, or abnormal behavior. Animals treated with VEGF demonstrated a significantly larger volume (42.90 ± 3.842 mm3) of T2 hyper-attenuation at 144 hours when compared with the volume (8.585 ± 1.664 mm3) in control animals (mean difference 34.31 ± 4.187 mm3, p < 0.0001, 95% CI 25.74-42.89 mm3). Postcontrast T1 enhancement in the juxtacanalicular region indicating BBB breakdown was observed in rats undergoing infusion with VEGF. At the later time periods (120-144 hrs) the volume of T1 enhancement (34.97 ± 8.99 mm3) was significantly less compared with the region of edema (p < 0.0001). Histologically, no evidence of necrosis or inflammation was observed with VEGF or control infusion. Immunohistochemical analysis demonstrated astrocyte activation, vascular remodeling, and increased claudin-5 expression in juxtacanalicular regions. Aquaporin-4 expression was increased in both control and VEGF animals in the juxtacanalicular regions. CONCLUSIONS The results of this study show that chronic brain infusion of VEGF creates a reliable model of VBE. This model lacks necrosis and inflammation that are characteristic of previous models of VBE. The model allows for a precise investigation into the mechanism of VBE formation. The authors also anticipate that this model will allow for investigation into the mechanism of glucocorticoid action in abrogating VBE, and to test novel therapeutic strategies targeting PTBE.

Entities:  

Keywords:  AQP4 = aquaporin-4; BBB = blood-brain barrier; CI = confidence interval; FITC = fluorescein isothiocyanate; FSE = fast spin-echo; GFAP = glial fibrillary acidic protein; IPH = intraparenchymal hemorrhage; PBS = phosphate-buffered saline; PTBE = peritumoral brain edema; ROI = region of interest; RSA = rat serum albumin; VBE = vasogenic brain edema; VEGF; VEGF = vascular endothelial growth factor; animal model; brain edema; cannula; infusion; peritumoral; rat; vasogenic

Mesh:

Substances:

Year:  2017        PMID: 28059647      PMCID: PMC5542877          DOI: 10.3171/2016.9.JNS1627

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  63 in total

1.  An angiogenic role for the α5β1 integrin in promoting endothelial cell proliferation during cerebral hypoxia.

Authors:  Longxuan Li; Jennifer Welser-Alves; Arjan van der Flier; Amin Boroujerdi; Richard O Hynes; Richard Milner
Journal:  Exp Neurol       Date:  2012-06-18       Impact factor: 5.330

2.  Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier.

Authors:  Carola Förster; Malgorzata Burek; Ignacio A Romero; Babette Weksler; Pierre-Olivier Couraud; Detlev Drenckhahn
Journal:  J Physiol       Date:  2008-02-07       Impact factor: 5.182

3.  Cold-injury of the cerebral cortex: immunolocalization of cellular proteins and blood-brain barrier permeability studies.

Authors:  S Nag
Journal:  J Neuropathol Exp Neurol       Date:  1996-08       Impact factor: 3.685

4.  Modelling convection-enhanced delivery in normal and oedematous brain.

Authors:  P J Haar; Z-J Chen; P P Fatouros; G T Gillies; F D Corwin; W C Broaddus
Journal:  J Med Eng Technol       Date:  2014-03

5.  Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals.

Authors:  M Tomás-Camardiel; J L Venero; A J Herrera; R M De Pablos; J A Pintor-Toro; A Machado; J Cano
Journal:  J Neurosci Res       Date:  2005-04-15       Impact factor: 4.164

6.  Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Authors:  John H Sampson; Gary Archer; Christoph Pedain; Eva Wembacher-Schröder; Manfred Westphal; Sandeep Kunwar; Michael A Vogelbaum; April Coan; James E Herndon; Raghu Raghavan; Martin L Brady; David A Reardon; Allan H Friedman; Henry S Friedman; M Inmaculada Rodríguez-Ponce; Susan M Chang; Stephan Mittermeyer; David Croteau; Raj K Puri
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

7.  Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis.

Authors:  J Strugar; D Rothbart; W Harrington; G R Criscuolo
Journal:  J Neurosurg       Date:  1994-10       Impact factor: 5.115

8.  Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme.

Authors:  Pascal O Zinn; Bhanu Mahajan; Bhanu Majadan; Pratheesh Sathyan; Sanjay K Singh; Sadhan Majumder; Ferenc A Jolesz; Rivka R Colen
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

Review 9.  Pathogenesis of brain edema and investigation into anti-edema drugs.

Authors:  Shotaro Michinaga; Yutaka Koyama
Journal:  Int J Mol Sci       Date:  2015-04-30       Impact factor: 5.923

10.  Complete rat spinal cord transection as a faithful model of spinal cord injury for translational cell transplantation.

Authors:  Dunja Lukovic; Victoria Moreno-Manzano; Eric Lopez-Mocholi; Francisco Javier Rodriguez-Jiménez; Pavla Jendelova; Eva Sykova; Marc Oria; Miodrag Stojkovic; Slaven Erceg
Journal:  Sci Rep       Date:  2015-04-10       Impact factor: 4.379

View more
  5 in total

1.  MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice.

Authors:  Brittany A Riggle; Sanhita Sinharay; William Schreiber-Stainthorp; Jeeva P Munasinghe; Dragan Maric; Eva Prchalova; Barbara S Slusher; Jonathan D Powell; Louis H Miller; Susan K Pierce; Dima A Hammoud
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-04       Impact factor: 11.205

2.  Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC.

Authors:  Yue Ren; Shan-Bing Wang; Lin Zhou; Si-Qiao Liu; Lei-Ya Du; Ting Li; Mao-Qiong Jiang; Kai-Jian Lei; Bang-Xian Tan; Yu-Ming Jia
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

3.  Preoperative Evaluation of Tumor Adhesion to Adjacent Brain Tissue in Patients with Meningioma with BSMI Method and Its Comparison with the Width of Edema Around Tumor

Authors:  Sonia Rezaei; Fariborz Faeghi; Mohammad Samadian; Babak Shekarchi
Journal:  Asian Pac J Cancer Prev       Date:  2018-07-27

4.  Meningioma preceding CASPR2 antibody limbic encephalitis with a stroke mimic: A case report.

Authors:  Xiao-Jin Lu; Ran Li; Yong-Xing Chen; Xian-Kai Xu; Bao-Lin Shi
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

Review 5.  Successful treatment using apatinib in intractable brain edema: A case report and literatures review.

Authors:  Yanqiu Song; Bailong Liu; Meng Guan; Min Liu
Journal:  Cancer Biol Ther       Date:  2018-08-06       Impact factor: 4.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.